← Back
AbCellera Biologics
ABCL · listed on Nasdaq · worth $4.13 billion
$12.08
−6.19% today
Eight insider buys in the last year, $2.11 million in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
209.0M shares
65% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought AbCellera Biologics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
10% owner
Thermopylae Holdings
Bought $580.3K on Feb 26 — 177,457 shares at $3.27, 0.3% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Director
Michael R. Hayden
Bought $481K on Aug 12 — 46,387 shares at $10.37, held through a trust or family, 3.5% of what they now own.
No earlier purchases to measure
Chief Financial Officer
Andrew Booth
Bought $383.9K on Aug 14 — 37,200 shares at $10.32, 7.7% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
All reports
Every insider trade and SEC report we hold for AbCellera Biologics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 14BoughtMichael R. HaydenAug 14 · Traded Aug 12 · Director+3.5%via a trust or family46,387 @ $10.37$481K
3 more with Pro →Analysts, earnings and news
Analysts' price target
$10.43 average
7 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26−$0.14 a share+$0.06
Q4 '25−$0.03 a share+$0.15
Q3 '25−$0.19 a share−$0.03
Q2 '25−$0.12 a share+$0.04